$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How much does a box of NTRK gene fusion targeting drug larotrectinib cost? Where can I buy it?
2025-10-19 11:44:20
Check Details
How should larotrectinib, which is different from traditional targeted drugs targeting the primary site, be taken?
2025-10-19 11:44:20
Check Details
Larotrectinib can be used to treat patients with NTRK gene fusions_Canghule
2025-10-19 11:44:20
Check Details
Activity and safety of crizotinib (Xalkori) in ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Efficacy of Lorlatinib
2025-10-19 11:44:20
Check Details
Learn more about the new anti-cancer drug Sotorasib about non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Mobocertinib receives FDA priority review status for the treatment of exon 20 mutated non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Do you know the main diagnostic methods for lung cancer?
2025-10-19 11:44:20
Check Details
The effect of Lorlatinib in the first-line treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How effective is lorlatinib treatment?
2025-10-19 11:44:20
Check Details
The efficacy and safety of dacomitinib (Dozerun) in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
The efficacy of dacomitinib (Duozerun) in lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
3913
3914
3915
3916
3917
3918
3919
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
2
Vemurafenib (Zelboraf) Complete Medication Guide
3
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
4
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
5
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
6
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
7
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
8
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
9
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
10
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
11
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity
12
Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments